In the present study, we demonstrated that aspirin had two different aspects of antitumor activity in PIK3CA-mutated CRC cells: (i) inhibitory effects on the mTOR pathway and the induction of G1 arrest and (ii) promotion of glutaminolysis and combinatorial effects with glutaminolysis-targeting agents (Figure 6g). Here, MTOR is linked to colorectal carcinoma.